Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Publication of AR098884A1publicationCriticalpatent/AR098884A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Investigating Or Analysing Biological Materials
(AREA)
Abstract
Métodos para identificar y tratar pacientes con cáncer que tienen alteraciones de activación en el dominio PEST de Notch1, Notch2 o Notch3 (Proteínas transmembrana), con un inhibidor de la vía de señalización de Notch, tal como el inhibidor de g-secretasa PF-03084014, o una sal de aquel aceptable desde el punto de vista farmacéutico. Dominio PEST (Prolina P, Ácido Glutámico E, Serina S, Treonina T). Uso. Compuesto.Methods for identifying and treating cancer patients who have activation disorders in the PEST domain of Notch1, Notch2 or Notch3 (Transmembrane proteins), with a Notch signaling pathway inhibitor, such as the G-secretase inhibitor PF-03084014 , or a salt thereof pharmaceutically acceptable. PEST domain (Proline P, Glutamic Acid E, Serine S, Threonine T). Use. Compound.
ARP140104823A2013-12-202014-12-19
NOTCH ACTIVATION CHANGES IN BREAST CANCER
AR098884A1
(en)
Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)